These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17394902)

  • 21. The benefit of a second burst antitachycardia sequence for fast ventricular tachycardia in patients with implantable cardioverter defibrillators.
    Anguera I; Dallaglio P; Sabaté X; Nuñez E; Gracida M; Di Marco A; Sugrañes G; Cequier A
    Pacing Clin Electrophysiol; 2014 Apr; 37(4):486-94. PubMed ID: 24215374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dilemma of ICD implant testing.
    Swerdlow CD; Russo AM; Degroot PJ
    Pacing Clin Electrophysiol; 2007 May; 30(5):675-700. PubMed ID: 17461879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shock Reduction With Multiple Bursts of Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators: A Multicenter Study.
    Anguera I; Dallaglio P; Martínez-Ferrer J; Rodríguez A; Alzueta J; Pérez-Villacastín J; Porres JM; Viñolas X; Fontenla A; Fernández-Lozano I; García-Alberola A; Sabaté X
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):774-82. PubMed ID: 25916814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators.
    Kouakam C; Lauwerier B; Klug D; Jarwe M; Marquié C; Lacroix D; Kacet S
    Am J Cardiol; 2003 Jul; 92(1):26-32. PubMed ID: 12842240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
    J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator.
    Neglia JJ; Krol RB; Giorgberidze I; Mathew P; Lewis C; Munsif AN; Saksena S
    J Interv Card Electrophysiol; 1997 Feb; 1(1):49-56. PubMed ID: 9869951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.
    Gasparini M; Proclemer A; Klersy C; Kloppe A; Lunati M; Ferrer JB; Hersi A; Gulaj M; Wijfels MC; Santi E; Manotta L; Arenal A
    JAMA; 2013 May; 309(18):1903-11. PubMed ID: 23652522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of first ventricular tachycardia cycle length on rate of ventricular arrhythmia recurrence in patients with implantable cardioverter-defibrillator.
    Arya A; Haghjoo M; Nikoo MH; Dehghani MR; Fazelifar AF; Sadr-Ameli MA
    J Electrocardiol; 2006 Oct; 39(4):404-8. PubMed ID: 16895771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristics.
    Sterns LD; Auricchio A; Schloss EJ; Lexcen D; Jacobsen L; DeGroot P; Molan A; Kurita T
    Heart Rhythm; 2023 Feb; 20(2):190-197. PubMed ID: 36272710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia?
    Sweeney MO; Ruetz LL; Belk P; Mullen TJ; Johnson JW; Sheldon T
    J Am Coll Cardiol; 2007 Aug; 50(7):614-22. PubMed ID: 17692746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks.
    Joung B; Lexcen DR; Ching CK; Silver MT; Piccini JP; Sterns LD; Rabinovich R; Pickett RA; Liu S; Brown ML; Cheng A
    Heart Rhythm; 2020 Jan; 17(1):98-105. PubMed ID: 31369873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST.
    Sterns LD; Meine M; Kurita T; Meijer A; Auricchio A; Ando K; Leng CT; Okumura K; Sapp JL; Brown ML; Lexcen DR; Gerritse B; Schloss EJ
    Heart Rhythm; 2016 Jul; 13(7):1489-96. PubMed ID: 26988379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and characteristics of type-2 breaks in response to antitachycardia pacing therapy in implantable cardioverter defibrillator patients.
    Sharma V; DeGroot PJ; Wathen MS
    J Cardiovasc Electrophysiol; 2003 Nov; 14(11):1156-62. PubMed ID: 14678127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results.
    Auricchio A; Schloss EJ; Kurita T; Meijer A; Gerritse B; Zweibel S; AlSmadi FM; Leng CT; Sterns LD;
    Heart Rhythm; 2015 May; 12(5):926-36. PubMed ID: 25637563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of ENHANCED Implantable Cardioverter Defibrillator Programming to Reduce Therapies and Improve Quality of Life (from the ENHANCED-ICD Study).
    Mastenbroek MH; Pedersen SS; van der Tweel I; Doevendans PA; Meine M
    Am J Cardiol; 2016 Feb; 117(4):596-604. PubMed ID: 26732419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.